Q4 2025 · 13F-HR
ACORN CAPITAL ADVISORS, LLCholdings as filed
Filed 2026-02-17 · accession 0001636587-26-000005
$295.1M
Reported value
21
Positions
2025-12-31
Period end
The Brief · ACORN CAPITAL ADVISORS, LLC · Q4 2025
AI · grounded in 13F
ACORN CAPITAL ADVISORS, LLC established a new position in ATHIRA PHARMA INC. LONA valued at $3.79M. The fund increased its holdings in CYBIN INC HELP by 114.19% and VERASTEM INC VSTM by 88.47%. Conversely, the fund nearly exited its position in VYNE THERAPEUTICS INC VYNE, reducing share count by 99.76%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $70.5M | 23.9% | 1,746,264 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $47.0M | 15.9% | 1,131,501 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $33.9M | 11.5% | 1,448,420 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $26.9M | 9.10% | 2,144,844 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $24.6M | 8.33% | 4,131,299 | Common | SOLE |
| 137404109 | CADL | CANDEL THERAPEUTICS INC | $14.6M | 4.94% | 2,580,517 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $12.9M | 4.36% | 1,573,023 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $11.3M | 3.84% | 1,469,153 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS | $10.8M | 3.67% | 643,382 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $9.3M | 3.16% | 1,752,115 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $8.2M | 2.79% | 2,839,674 | Common | SOLE |
| 14147L108 | CRDF | CARDIF ONCOLOGY INC | $5.5M | 1.87% | 1,962,084 | Common | SOLE |
| 04746L203 | LONA | ATHIRA PHARMA INC. | $3.8M | 1.29% | 501,739 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS | $3.3M | 1.11% | 1,786,492 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $3.2M | 1.10% | 595,744 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $2.8M | 0.93% | 1,139,363 | Common | SOLE |
| 09077B104 | BCABGBP | BIOATLA INC | $2.8M | 0.93% | 4,835,111 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC. | $1.6M | 0.56% | 493,425 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $1.1M | 0.37% | 273,349 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $976,622 | 0.33% | 405,237 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $827 | 0.00% | 1,425 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.